Abstract: The present invention relates to a method for the cosmetic treatment of keratin materials, comprising the application of a composition to the keratin materials, such as the skin, said composition comprising a compound (I), wherein R1, R2 and R3 are as defined in the description and S* is a mono or polysaccharide.
Abstract: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of neohesperidin or a neohesperidin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using neohesperidin. The skin microcirculation of the present invention is preferably eye skin microcirculation.
Abstract: Provided is a novel peptide and a cosmetic composition for inhibiting a skin-aging or a skin-wrinkle formation including the same. The peptide has activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins significantly.
Type:
Application
Filed:
October 30, 2017
Publication date:
September 12, 2019
Applicant:
College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation
Abstract: The invention relates to a cosmetic composition comprising at least one cationic derivate of fructan and at least one anionic surfactant, non-ionic surfactant or amphoteric surfactant. The cationic derivate of fructan has preferably a molecular weight of less than 30000 g/l and preferably a solubility in water at a temperature of 25° C. of at least 20 wt %. The invention further relates to a method for treating hair with such a cosmetic composition.
Type:
Application
Filed:
March 6, 2019
Publication date:
September 12, 2019
Applicants:
Cosun Food Technology Center, Coöperatie Koninklijke Cosun U.A.
Inventors:
Tom Willem Louis Brooijmans, Harry Raaijmakers, Carlos Maria van Kats
Abstract: A personal care composition is provided, comprising: a vehicle; a surfactant, wherein the surfactant includes at least one alkyl polyglucoside; a water-soluble cellulose ether base material substituted with a hydrophobic group having a carbon chain with 8 to 15 carbon atoms; wherein the water-soluble cellulose ether base material has a weight average molecular weight, Mw, of >800,000 Daltons; and wherein the personal care composition contains <0.01 wt % alkyl sulfate and <0.01 wt % alkyl ether sulfate.
Type:
Application
Filed:
August 17, 2017
Publication date:
September 12, 2019
Inventors:
Lyndsay M. Leal, Katherine R. Davis, Emmett M. Partain, III, Nikhil J. Fernandes, Eric P. Wasserman
Abstract: This document relates to methods and materials involved in providing a tooth, tooth component, or inorganic dental material (e.g., a human tooth, a human tooth component, or an inorganic dental material within a human's mouth) with a white appearance. For example, a whitening adhesive containing a conjugate of at least a polyamine, a polyphosphate, and one or more whitening agents (e.g., titanium dioxide, zinc oxide, and/or hydroxyapetite) can be used to provide a tooth, tooth component, or inorganic dental material with a whiter appearance.
Type:
Application
Filed:
December 28, 2018
Publication date:
September 12, 2019
Applicant:
SafeWhite, Inc.
Inventors:
Satish Kumar Garre Venkata Raghavendra, Gary Fred Musso, Caitlin Marie Kiracofe, Ada Alicia Sierraalta, Michelle Anne Hurtubise, Carlos Eduardo Martinez, Deepti Gupta
Abstract: The present invention relates to an aqueous dispersion of polyalkene supramolecular polymer with a surfactant system chosen from an anionic surfactant, a cationic surfactant and a non-ionic surfactant. The invention also relates to a cosmetic composition comprising such a dispersion. Use for caring for and making up keratin materials.
Abstract: A nail cosmetic composition contains a silicone macromonomer as a base material having at least two polymerizable functional groups and a polymerization initiator with respect to the silicone macromonomer. A method of using a nail cosmetic composition includes a painting step of painting a nail cosmetic composition described above on a nail and a curing step of exposing the nail cosmetic composition to light with an illuminance of 80 mW/cm2 or less at dominant wavelength at an exposure time within three minutes per one layer to cure the nail cosmetic composition. The nail cosmetic resin contains a silicone unit in which a silicone macromonomer has been polymerized as the base material having at least two polymerizable functional groups.
Abstract: This invention relates to prebiotic cosmetic compositions comprising at least one ingredient with prebiotic activity selected from sugars, oils and extracts for the treatment of signs of aging on the skin, fostering well-balanced skin, nourishing beneficial micro-organisms in the skin biota, protecting it from harsh environmental aspects, strengthening it, reducing sensitivity and irritations, and improving its defense system.
Type:
Application
Filed:
November 10, 2016
Publication date:
September 12, 2019
Inventors:
Luciana DE MIRANDA CHAVES VASQUEZ PINTO, Débora DOMENES PALMIERI RODRIGUEZ
Abstract: The present invention relates to a composition comprising: (a) at least one botanical butter; (b) at least one alkaline agent comprising at least one primary amino group and at least three hydroxyl groups; (c) at least one wax; and (d) water. The composition according to the present invention does not produce NDELA, because it does not need to use TEA, but it can provide keratin fibers such as eyelashes with enhanced or improved cosmetic effects or properties, such as excellent volumizing effects (e.g., the thickness of keratin fibers is increased) and even application effects (e.g., the composition can be applied evenly onto keratin fibers to clean appearance of the keratin fibers).
Abstract: The present application discloses modified release mucoadhesive formulations of mycophenolate mofetil and pharmaceutical compositions thereof useful in the treatment of, for example, post-transplant organ rejection. Method of preparing the formulations is also disclosed.
Type:
Application
Filed:
March 4, 2019
Publication date:
September 12, 2019
Applicant:
University of Saskatchewan
Inventors:
Ellen K. Wasan, Ahmed Shoker, Holly G. Mansell, Kishor M. Wasan
Abstract: A method for delivery of one or more active agents into the pulmonary system of a subject using liquid foam is provided. The invention further provides a pulmonary drug delivery device for providing a liquid foam to a target site of a respiratory system.
Abstract: The present document describes a method of preventing or treating a hoof bacterial infection on at least one hoof of a live hoofed animal having a bacterial presence thereon with an antibacterial formulation comprising: a) at least one antimicrobial isolated or synthetic phenolic compound of natural origin; b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in water; c) a solvent for dissolving said phenolic compound; and d) a sufficient water quantity to make 100% (w/w).
Type:
Application
Filed:
April 2, 2019
Publication date:
September 12, 2019
Inventors:
Gaetan LEMIRE, Ulysse DESRANLEAU DANDURAND, Sylvain QUESSY, Ann LETELLIER
Abstract: A composition is in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, and includes at least: insulin glargine, a co-polyamino acid bearing carboxylate charges and hydrophobic Hy radicals, the co-polyamino acid being made of glutamic or aspartic units and the hydrophobic Hy radicals from following formula I below: *?GpR?r?GpA?a?GpC)p?? Formula I The composition does not include a basal insulin whose isoelectric point pI is from 5.8 to 8.5. A composition further includes prandial insulin.
Abstract: A composition in the form of an injectable aqueous solution, wherein the pH is comprised from 6.0 to 8.0, includes at least: a) amylin, an amylin receptor agonist or an amylin analog; and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, wherein the composition does not comprise a basal insulin wherein the isoelectric point pI is comprised from 5.8 to 8.5. The composition may further include a prandial insulin.
Type:
Application
Filed:
December 7, 2018
Publication date:
September 12, 2019
Applicant:
ADOCIA
Inventors:
You-Ping Chan, Alexandre Geissler, Romain Noel, Walter Roger, Richard Charvet, Nicolas Laurent
Abstract: The invention relates to nanodevices for the controlled release of substances which comprises a support coated in oligosaccharides, wherein said oligosaccharides comprise at least 3 units of monosaccharides, and wherein at least one of the monosaccharides is galactose. These nanodevices release their load specifically in senescent cells. The invention also encompasses the method of obtainment and its uses.
Type:
Application
Filed:
May 7, 2019
Publication date:
September 12, 2019
Inventors:
Ramón Martínez Máñez, José Ramón Murguia Ibáñez, Rosario Perona Abellón, Alessandro Agostini, Laura Mondragón Martínez, Marta Moreno Torres, Cristina Manguan García, María Dolores Marcos Martínez, Juan Soto Camino, Felíx Sancenón Galarza
Abstract: The present invention relates to: biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate; a preparation method therefor; and a method for treating cancer using the same. The microbeads of the present invention is prepared from a biocompatible and biodegradable polymer so as to be safe to the human body, and can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrition to a liver tumor and continuously releasing an anticancer drug adsorbed on surfaces of the beads. Therefore, the present invention can be useful for liver cancer chemoembolization.
Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm? area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.
Type:
Application
Filed:
May 13, 2019
Publication date:
September 12, 2019
Inventors:
Keith P. JOHNSTON, Joshua ENGSTROM, Robert O. WILLIAMS, III
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Type:
Application
Filed:
March 12, 2019
Publication date:
September 12, 2019
Applicant:
Vertex Pharmaceuticals Incorporated
Inventors:
Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
Abstract: A colon-targeted composition of a biological active component is disclosed, as well as formulations and preparation methods thereof. The colon-targeted composition of a biological active component includes in weight percentage: 10-99% hydroxypropyl methylcellulose, 1-60% biological active component and 0-80% auxiliary material, wherein the viscosity of hydroxypropyl methylcellulose is greater than 1,000 mPa·s. The colon-targeted composition of a biological active component has an improved colon-targeted effect and improves the bioavailability and in vivo activity of the biological active component.
Abstract: The present invention relates to an improved powdered extrudate based on polyvinyl alcohol (PVA), which can be used for the production of pharmaceutical products, and due to its improved properties, can be better directly compressed into tablets. Furthermore, this invention refers to pharmaceutical tablets composition comprising extruded polyvinyl alcohol as carrier matrix, which is suitable to improve the solubility of API within a controlled release (instant or sustained) kinetic.
Type:
Application
Filed:
November 6, 2017
Publication date:
September 12, 2019
Applicant:
Merck Patent GmbH
Inventors:
Mengyao ZHENG, Nicole DI GALLO, Anja-Nadine KNUETTEL
Abstract: The present invention relates to a preparation method for a traditional Chinese medicine drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, the present invention relates to a micro drop pill preparation method with high drug-loading capacity, simple preparation process and high production rate and a micro drop pill prepared by using the method. Specially, The drop pill preparation method used comprises the following steps: (1) material melting step: heat melting a medicine and a drop pill matrix to obtain a molten medicine liquid; (2) dropping step: delivering the molten medicine liquid to a dripper, and acquiring medicine drops of the molten medicine liquid by means of vibration dropping; and, (3) condensation step: cooling the medicine drops with a cooling gas to obtain micro drop pills.
Abstract: A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders; and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.
Type:
Application
Filed:
March 7, 2019
Publication date:
September 12, 2019
Inventors:
Il Mo Kang, Dae Duk Kim, Ju Hwan Park, Ki Min Roh, Jangik Ike Lee, Jae Hwan Kim, Sung Man Seo, Su Young Jung
Abstract: The invention relates to an immediate and sustained release composition, a dose unit or a two compartment package comprising the composition as well as use and a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract.
Type:
Application
Filed:
August 21, 2017
Publication date:
September 12, 2019
Inventors:
Salih Muhsin Muhammed, Katarina Lindell
Abstract: The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of an antiemetic agent in particular Aprepitant and an effective amount of surface stabilizer in order to improve bioavailability. It also relates to a process for the preparation thereof.
Abstract: This invention presents a method for preparing casein-based silica dual drug-loaded composite microcapsule. Recently, casein has shown good application prospects in the field of medicine due to its good biocompatibility and unique cavity structure. However, research on preparation of casein-based dual drug-loaded microcapsules is still rarely reported. In this invention, dual drug-loaded casein microcapsules is obtained via interfacial polymerization method, where drug-loaded casein can be used as outer shell material in capsule, and silica is served as inner shell in the capsule. In the obtained microcapsule, drugs can not only be loaded in the inner cavity, but also in casein shell. Application of the dual drug-loaded microcapsules in the treatment of diseases is expected to reduce the number of dose to a certain extent and improve the therapeutic effect.
Abstract: A composition includes sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate which includes ferrous ions and an amino acid. The sintered ferrous amino acid particles have an average particle size ranging from 500 to 2600 nm and a weight average molecular weight ranging from 1,500 Dalton to 600,000 Dalton. Also disclosed herein are a method for inhibiting and/or killing a virus in a subject and applications of such method. The method includes administering to the subject the composition.
Type:
Application
Filed:
December 18, 2018
Publication date:
September 12, 2019
Inventors:
Tsun-Yuan LIN, Mu-Kuei CHEN, Kai-Ting WANG, Hsun-Jin JAN
Abstract: The present invention generally relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.
Type:
Application
Filed:
October 27, 2017
Publication date:
September 12, 2019
Inventors:
Drew Weissman, Norbert Pardi, Ying Tam, Michael J. Hope
Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of caryophyllene to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain embodiments, the drugs are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream, gel, lotion or foam.
Abstract: The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis or symptoms associated therewith. Furthermore, the present invention provides a pharmaceutical kit for the therapy of anterior or posterior blepharitis or symptoms associated therewith.
Type:
Application
Filed:
September 20, 2017
Publication date:
September 12, 2019
Inventors:
Bernhard GÜNTHER, Frank LÖSCHER, Sonja KRÖSSER
Abstract: A composition and method for the use of Panax quinquefolius for the attenuation of Cannabis-induced dysphoria where dosage can be effectively administered in a gum base cold pressed into a tablet containing at least 300 mg of Panax quinquefolius and Maltitol, Sorbitol, Isomalt, Xylitol, natural & artificial flavors, vegetarian magnesium stearate, Sucralose and Silicon dioxide. A composition and method for the use of falcarinol for the the attenuation of Cannabis-induced dysphoria and reverse cannabis tolerance where the dosage of at least 30 mg can be effectively administered for buccal absorption.
Type:
Application
Filed:
May 30, 2019
Publication date:
September 12, 2019
Inventors:
PAUL EPNER, RICHARD ZIMMER, III, BILL W. MASSEY
Abstract: Disclosed herein is an alkaline water solution including CBD oil mixed homogeneously with the alkaline water. In a second exemplary embodiment, Fulvic Acid is added to the solution of CBD oil and alkaline water. In general, the CBD oil makes up no more than 3% of the alkaline water solution and no more than 2000 mg in a 15 ounce container. In the solution including Fulvic Acid, a 15 ounce solution contains between 5 mg and 15 mg.
Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
Abstract: The use of tapentadol for the treatment of pain associated with disorders of the trigeminal nerve, in particular for use in the treatment of pain associated with trigeminal neuralgia.
Type:
Application
Filed:
May 28, 2019
Publication date:
September 12, 2019
Applicant:
GRUENENTHAL GMBH
Inventors:
Thomas CHRISTOPH, Jean De Vry, Thomas Tzschentke, Petra Bloms-Funke, Klaus Schiene, Michel Hamon
Abstract: Elastogenic nanoparticles including a polymeric core having a surface that is functionalized with a cationic amphiphilic compound, and comprising an active agent having pro-elastogenic and/or anti-proteolytic activity, are described herein. The elastogenic nanoparticles can be used in method of stimulating elastogenesis in a subject by administering to the subject a therapeutically effective amount of elastogenic nanoparticles.
Abstract: The present invention relates to the treatment of mixed lineage leukemia. In particular, the present invention relates to therapies involving the induction of proteolysis of the MLL fusion proteins that result from the chromosomal translocations affecting the MLL gene at 11q23.
Abstract: Compositions and methods for treating skin redness. According to an embodiment, the invention is a topical skin care composition having a dermatologically acceptable vehicle, such as, water and a plurality of ingredients dissolved in the vehicle. The ingredients include: a blend of natural oils; a plurality of vitamins; and 0.1-1 wt % salicyloyl phytosphingosine. The composition is unsuitable for application on the eyelids or eye area. The blend of natural oils includes: aloe barbadensis leaf juice extract; cocos nucifera (coconut oil); hydrolyzed glycosaminoglycans; and caprylic/capric triglycerides. The plurality of vitamins is selected from a group consisting of vitamin C, vitamin E, salts/derivatives of vitamin C and vitamin E, and mixtures thereof. In one aspect, the plurality of vitamins includes: sodium ascorbyl phosphate; disodium lauriminodipropionate tocopheryl phosphate; and jojoba oil.
Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising a salicylamide compound and an agent that increases the permeability of a bacterial cell membrane for use in treating or preventing bacterial infections.
Type:
Application
Filed:
May 18, 2017
Publication date:
September 12, 2019
Inventors:
David Francis Ackerley, Janine Naomi Copp
Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
Type:
Application
Filed:
November 24, 2016
Publication date:
September 12, 2019
Applicants:
Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
Abstract: A method of increasing mesenchymal stromal cell osteogenic potential in a patient comprising administering to the patient a therapeutic that inhibits Notch signaling. A method of stimulating one of bone tissue regeneration and bone tissue formation in a mammal comprising administering to the mammal a first therapeutic containing Oleanolic acid. A pharmaceutical product comprising a first therapeutic containing Oleanolic acid or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.
Abstract: A composition comprising, as an active principle, a pharmaceutically acceptable salt of elafibranor, characterised in that the pharmaceutically acceptable salt of elafibranor is chosen from at least a salt of choline, of ethanolamine, or of diethanolamine, or of L-lysine, or of piperazine, or of calcium, or of tromethamine. More particularly, one or more embodiments relate to the use of elafibranor salts with a view to improving stability and solubility compared with elafibranor in the basic form thereof. These salts make it possible to establish pharmaceutical formulations in various advantageous forms as intravenous injections or formulations by enteral route having quicker and less variable absorption and consequently better bioavailability.
Abstract: The disclosure provides compositions comprising desaminotyrosine and methods of use thereof in enhancing type I interferon stimulation, epithelial proliferation, and treatment of inflammatory bowel disease.
Type:
Application
Filed:
October 26, 2017
Publication date:
September 12, 2019
Applicant:
Washington University
Inventors:
Thaddeus Stappenbeck, Ashley Steed, Gerard Kaiko, George Christophi
Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
Type:
Application
Filed:
April 24, 2019
Publication date:
September 12, 2019
Applicant:
SyneuRx International (Taiwan) Corp.
Inventors:
Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
Abstract: Provided is a method of producing a purified chlorogenic acid-containing composition, including a contact step of bringing a chlorogenic acid-containing composition having solids concentration of from 1.5 mass % to 4.7 mass % and a “caffeine/chlorogenic acid” mass ratio of 5 or less into contact with a porous adsorbent.
Abstract: The present invention relates to sterile injectable compositions comprising melphalan and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.
Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
Type:
Application
Filed:
February 20, 2019
Publication date:
September 12, 2019
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Bruce A. Freeman, Francisco J. Schopfer
Abstract: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present disclosure describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.
Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
Type:
Application
Filed:
February 19, 2019
Publication date:
September 12, 2019
Inventors:
Mehar Manku, John Climax, David Coughlan, James Dunne